Protagenic’s Neuropeptide Shows Strong Efficacy in Treating Depression and Anxiety of Established Rodent Models
First in class psychotropic agent 50% reduction in anxiety related symptoms Data generated by independent world-renowned laboratory NEW YORK, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB:PTIX) announced today that experiments …